PRESS-RELEASE ·Filed Jul 28, 2026
Press release · FDA
Actionable Insight • Neutral
Monitor for Part A data release, which could serve as a catalyst.
Final — all horizons settled through T+60d
CMND ▼ -49.14% at T+60d
NEUTRAL call -49.14% · α vs SPY -53.49% · entry $1.46 → $0.7425
T+1d
0.00%
call 0.00% · α +1.54%
$1.46
settled 3mo ago
T+5d
+17.12%
call +17.12% · α +13.01%
$1.71
settled 3mo ago
T+20d
+17.12%
call +17.12% · α +13.74%
$1.71
settled 2mo ago
T+60d
-49.14%
call -49.14% · α -53.49%
$0.7425
settled 6d ago
Price Chart
Loading chart...
Executive Summary
Clearmind Medicine announced completion of treatment for all 24 participants in Part A of its Phase I/II trial for CMND-100 in alcohol use disorder. No clinical data were released; the company is reviewing the dataset before initiating the next study stage. This is a routine procedural milestone with no material financial impact.
Key Facts
- All 24 participants across cohorts 1-4 completed Part A treatment per protocol.
- Trial conducted under FDA oversight at Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah Medical Center.
- No clinical efficacy or safety data disclosed; data review is ongoing.
- Company intends to initiate next stage if results remain favorable.
Financial Impact
No financial figures disclosed; clinical-stage company with no revenue.
Risk Factors
- Clinical trial data may be unfavorable or inconclusive.
- Company is a micro-cap with limited cash runway; future funding may be needed.
- Forward-looking statements carry inherent uncertainty; no guarantee of next-stage initiation.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3334151 |
63 reports for CMND
53% Hit rate @ T+60 Went positive at some point 16 of 21 best @ T+60▲ +75.73%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
Showing 10 of 63
US Market Status
Market Closed — Opens in 9h 14m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers